Overview
The basic premise of this pilot study is to enroll 40 patients over 3 years who have Stage III or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradiation where a contrast enhanced 4DCT is planned..
Eligibility
Inclusion criteria:
- Patients have histologic diagnosis of non-small cell lung cancer
- Patients have AJCC stage II, III or IV disease were the plan is to receive definitive concurrent chemoradiation to 60 Gy or higher
- Age > 18 years of age
- Patients are able to provide informed consent
- No additional lung radiation is planned until after the 2nd CT on this study (i.e. patient does not have a solitary pulmonary nodule or second primary that the plan is to undergo SBRT)
- Patient must have adequate kidney function to receive IV contrast (following institutional policy supplied by radiology). The cutoff level for serum creatinine is 1.6 mg/dL
- Negative urine pregnancy test before every CT scan
Exclusion criteria:
- Allergy to IV iodine contrast
- Severe claustrophobia
- Further thoracic radiation therapy is planned.